Westside Eye Doctors CPD Night July 2025
Date: 23/07/2025 (AEST)
Venue: 100 Boundary Street, West End, QLD, 4101
Provider: Westside Eye Doctors
Contact: Sheue-Lee Ooi, [E] hello@westsideeyedoctors.com.au, [P] 07 3188 5185
Activity Outline
This series of presentations offers a thorough review of recent clinical advances in ophthalmology, with a strong emphasis on evidence-based practice and patient-centred care.
Part one of Dr. Lily Sheue-lee Ooi’s talk explores the evolving landscape of glaucoma management, highlighting innovations in diagnostics like OCT angiography and emerging biomarkers for early risk stratification. The role of selective laser trabeculoplasty (SLT) as a primary therapy is reassessed in light of new randomized trials such as the LiGHT study. Pharmacological updates include fixed-dose combinations and sustained-release therapies, with emphasis on adherence and tolerability. Minimally invasive glaucoma surgery (MIGS) is reviewed through recent comparative trials, focusing on long-term intraocular pressure control. The session integrates case-based discussions to apply research in both resource-rich and constrained healthcare settings.
Part two of her talk reviews contemporary management of diabetic retinopathy (DR) and diabetic macular oedema (DMO). Advances in screening—using OCT/OCTA and ultra-widefield imaging—enhance early detection of progression-prone peripheral lesions. Key clinical trials inform the use of anti-VEGF agents, corticosteroids, laser treatment, and newer innovations like faricimab, biosimilars, and sustained-release intravitreal implants. Systemic risk control strategies, based on ACCORD and UKPDS findings, are emphasized. Practical cases demonstrate how treat-and-extend protocols and biomarker-driven approaches support personalized care.
Dr. Liam Turner focuses on periocular tumours and lower eyelid malposition. His tumour review includes diagnosis and management of basal and squamous cell carcinomas, with insights into margin control techniques and the role of immunotherapy in high-risk cases. His session on eyelid malposition addresses entropion and ectropion, exploring underlying causes and outlining both medical and surgical interventions.
Together, these sessions translate emerging research into actionable strategies for daily practice across subspecialties.
Learning Objectives
- Learn about the latest development in glaucoma management
- Evidence based lifestyle advise for glaucoma patient
- Learn about the latest evidence based diabetic retinopathy and maculopathy treatment
- Learn about various eyelid tumours
- Learn about how to recognise malignant conditions
- Review normal eyelid anatomy and referral recommendation.
Max CPD hours awarded: 3
Session Information
| Name |
|---|
| Review of Recent Evidence in Glaucoma Management |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.75 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 0.75 |
| Name |
|---|
| Recent Evidence in the Management of Diabetic Retinopathy and Diabetic Maculopathy |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.75 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 0.75 |
| Name |
|---|
| Review of Periocular tumours |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.75 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 0.75 |
| Name |
|---|
| Review of Eyelid Malposition Management |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.75 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 0.75 |